Journal
MOLECULES
Volume 23, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/molecules23051068
Keywords
amyloid-beta; monoclonal antibodies; posttranslational modifications; drug development
Funding
- NIH [R01 AG058657]
Ask authors/readers for more resources
Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer's disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid hypothesis, the majority of antibodies in clinical development are directed against amyloid (A), the primary amyloid component in extracellular plaques. This review focuses on the current status of A antibodies in clinical development, including their characteristics and challenges that came up in clinical trials with these new biological entities (NBEs). Emphasis is placed on the current view of common side effects observed with passive immunotherapy, so-called amyloid-related imaging abnormalities (ARIAs), and potential ways to overcome this issue. Among these new ideas, a special focus is placed on molecules that are directed against post-translationally modified variants of the A peptide, an emerging approach for development of new antibody molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available